The total return over the past 12 months is -21.02% vs. +16.94% for the S&P 500. So far it's up -28.08% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (21.02%) | (7.10%) | (13.07%) | +12.07% | (3.44%) | N/A |
| Total Return CAGR | (21.02%) | (7.10%) | (13.07%) | +12.07% | (3.44%) | N/A |
| Revenue CAGR | +6.65% | +4.81% | +7.25% | +17.56% | +15.58% | N/A |
| Net Income CAGR | (138.84%) | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | (135.59%) | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | (184.77%) | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | (172.50%) | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Champions Oncology, Inc. (CSBR)
| Year | Start price | End price | CSBR Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $6.91 | $4.97 | (28.08%) | +14.51% | (42.59%) |
| 2025 | $8.57 | $6.91 | (19.37%) | +17.72% | (37.09%) |
| 2024 | $5.62 | $8.57 | +52.49% | +24.89% | +27.60% |
| 2023 | $4.51 | $5.62 | +24.61% | +26.19% | (1.58%) |
| 2022 | $8.36 | $4.51 | (46.05%) | (18.17%) | (27.88%) |
| 2021 | $10.79 | $8.36 | (22.52%) | +28.74% | (51.26%) |
| 2020 | $8.33 | $10.79 | +29.53% | +18.37% | +11.16% |
| 2019 | $7.81 | $8.33 | +6.66% | +31.22% | (24.56%) |
| 2018 | $3.88 | $7.81 | +101.29% | (4.56%) | +105.85% |
| 2017 | $2.53 | $3.88 | +53.36% | +21.70% | +31.66% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
